ADC Therapeutics: volume-led sales and deeper cost cuts, as recapitalisation shifts focus to ASH
Q3 net product revenue of $21.0M and a 29% cut in adjusted opex narrowed the loss, while an October restructuring extended the company's expected cash runway into 2029.
The quarter in numbers
ADC Therapeutics reported third-quarter net product revenue of $21.0 million, up from $15.8 million a year earlier. For the nine months ended September 30, 2026, net product revenue was $59.7 million versus $51.2 million. By our calculation that is growth of about 33% for the quarter and 17% for the nine months. The company said the increase was primarily driven by volume. The release gives no price effect and no product-level or regional split, so ZYNLONTA's growth cannot be broken down further from this document.
License revenue and royalties were flat for the quarter at $0.7 million. The nine-month figure fell to $2.1 million from $7.1 million, which the company attributed primarily to a milestone received from a partner in the prior year.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Sources
- ADC Therapeutics SA: quarterly results release (SEC filing) SEC EDGAR · 09 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.
Tonix's TONMYA reaches $15M, but a $163M cash pile and a Paragraph IV filing frame the debate
Third-quarter net product revenue rose to about $17.2M, yet opex of $72.7M and a runway only into early Q3 2027 mean financing and patent litigation loom over the launch.
Inhibrx's Q3: Debt and launch prep push losses up as chondrosarcoma review looms
A $2.0 million Pfizer licence fee barely dented a $38.7 million net loss as interest costs and pre-commercial spend rose while R&D fell and the balance sheet moved into deficit.
Talphera's Q3: no revenue, a smaller per-share loss and an FDA bet on early NEPHRO enrollment close
With $14.2 million in cash and a pivotal CRRT study running short of its 70-patient target, Talphera is asking the FDA to accept a December 31, 2026 enrollment cutoff.